Bortenat Injection

Bortenat Injection is recommended for treating blood cancer like mantle cell lymphoma and multiple mueloma. This injection contains protesomes protein that has significant role in retarding proliferation of cancer affected cells. Approved by FDA, this pharmaceutical product is available in 2 mg and 3.5 mg quantity based options. Patients suffering from kidney disorder, liver complications, diabetes and inadequate white or red blood cells need to take precaution prior to using this injection. Bortenat Injection needs to be taken only after consulting with medical practitioner. This injection should be stored under 30 degree C temperature. Long lasting effectiveness is one of its key features.
Product Image (0130)

Bortenat Bortezomib 3.5 mg Injection

  • Delivery Time:7 Days
  • Supply Ability:10000 Per Month
  • Drug Type:Drug Solutions
  • Storage Instructions:Room Temperature (25 C Temperature)
  • Dosage Guidelines:As guided by physician
  • Dosage:Injection
  • Ingredients:Bortezomib 3.5 Mg
  • Physical Form:Liquid
  • Function:Anti-Cancer
Product Image (01)

Bortenat Bortezomib for Injection 2 mg

  • Delivery Time:7 Week
  • Supply Ability:10000 Per Month
  • Storage Instructions:Keep out of the reach and sight of children. Do not store above 30C. Keep the vial in the outer carton in order to protect from light. Do not use after the expiry date stated on the vial and the carton after EXP. The reconstituted solution should be used immediately after preparation. If the reconstituted solution is not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. However, the reconstituted solution is stable for 8 hours at 25 C in the original vial and/or a syringe prior to administration, with a maximum of 8 hours in the syringe.
  • Dosage Guidelines:As guided by physician
  • Quantity:per Box 1 vial Unit
  • Dosage:2 mg/ Vial
  • Ingredients:Bortezomib.
X


Back to top
trade india member
HEET HEALTHCARE PVT. LTD. All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.